News
Market and company headlines
MRKAll
Loading
18:00-21:00Yesterday2 Stories
Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts
Merck & Co., Inc. (NYSE:MRK) outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its sacituzumab tirumotecan, or sac-TMT, antibody-drug conjugate in endometrial cancer and its individualized neoantigen t
Merck & Co., Inc. (MRK) Shareholder/Analyst Presentation - Slideshow
2026-10-26. The following slide deck was published by Merck & Co., Inc.
13:00-15:00Yesterday3 Stories
Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
Merck & Co., Inc. (MRK) Shareholder/Analyst Call October 26, 2026 2:30 PM EDTCompany ParticipantsPeter Dannenbaum - Vice President of Investor...
Merck’s Endometrial Cancer Drug Cuts Risk Of Death By 32% – FDA Decision Due By June 2027
In the 776-patient Phase 3 trial, Sac-TMT-treated patients had a median overall survival of 19 months compared to 12.1 months for chemotherapy
Merck (MRK) Stock Gets Fair Value Bump As Analysts Split On Vaccine Outlook
Merck’s updated fair value estimate has shifted to US$159.76, compared with US$155.68 previously, which effectively nudges implied price targets higher for investors tracking intrinsic value. This move sits alongside a split in recent analyst commentary, with some pointing to the cancer vaccine partnership and broader oncology pipeline as support for higher targets, while others flag concerns about valuation and future earnings pressure. As you read on, you will see how this evolving...
09:00-13:00Yesterday2 Stories
What Do New China Biotech Curbs Mean For Merck (MRK) Stock?
Merck (NYSE:MRK) faces new U.S. Treasury restrictions on collaborations with certain Chinese biotech and AI firms announced in October 2026. This policy move targets U.S. investment and partnership flows into Chinese companies involved in advanced therapeutics and data-driven drug research. Limits on China partnerships could affect how Merck sources future cancer drug candidates and external research programs from that market. There is more to Merck than the new U.S. Treasury curbs on China...
Merck Endometrial Cancer Studies Show Significant Survival Gains
Merck reports positive Phase 3 data for Keytruda and sac-TMT in endometrial cancer, showing significant survival gains at ESMO 2026.
08:00Yesterday2 Stories
LLY vs. MRK: Which Stock Offers the More Compelling Investment Case?
Lilly and Merck boast blockbuster drugs, expanding pipelines and new growth opportunities but pricing pressure, patent risks & competition shape their outlooks.
Countdown to Merck (MRK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Get a deeper insight into the potential performance of Merck (MRK) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
11:00Oct 251 Story
03:00Oct 241 Story
12:00-16:00Oct 232 Stories
AbbVie’s Dividend Survived Humira’s Patent Cliff. Will Merck and Amgen’s?
When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one sits to the edge varies far more than the yields suggest.
Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?
Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data.
09:00-12:00Oct 232 Stories
Merck CEO Plays Down Cost Concerns Over Intismeran — ‘We Don't See Cost As A Limit To Access’
In an interview with CNBC, Merck CEO Rob Davis said the company is confident it can deliver Intismeran at scale.
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding after an 18% collapse. The selloff raises a pointed question about whether the data actually delivered what investors spent months betting on.
06:00Oct 232 Stories
Moderna And Merck Cancer Vaccine Cuts Melanoma Death Risk By 42%
Key Stats for Merck StockPrice change for Merck stock in last 6 months: 28%$MRK Stock Price as of Oct. 21: $14752-Week High: $157$MRK Stock Price Target: $159__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__>>> What Happened?Moderna and Merck (MRK:NYSE) shared results from a large melanoma trial on Thursday.
Merck CEO on melanoma vaccine results: The prescribing community will find results quite meaningful
Merck CEO Rob Davis joins 'Squawk on the Street' to discuss leaked data of melanoma vaccine trials, the drop off the company's stock price and more.
16:00-19:00Oct 222 Stories
Merck (MRK) Wins EU Approval For KEYTRUDA Plus Padcev In Bladder Cancer
Merck (NYSE:MRK) received European Commission approval for KEYTRUDA plus Padcev as a perioperative therapy for resectable muscle-invasive bladder cancer in the EU. The decision covers patients regardless of cisplatin eligibility, widening access to the regimen across a broader bladder cancer population. This is the first European Union authorization for a PD-1 inhibitor used with an antibody-drug conjugate in this disease setting. The European Commission approval of KEYTRUDA plus Padcev in...
Merck Won a Wider EU Bladder Cancer Label for Keytruda. Here’s What Its ESMO Data Needs to Show
Key Stats for Merck StockCurrent Price: $149. 88Target Price (Mid): ~$161Street Target: ~$159Potential Total Return: ~8%Annualized IRR: ~2% / year__Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)__ >>> What Happened?Merck (MRK) won a wider European Union label for Keytruda plus Padcev in muscle-invasive bladder cancer on October 21.
15:00Oct 222 Stories
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction,” one analyst wrote.
Merck, Moderna Unveil Cancer Vaccine Data — After A Leak Stole Their Thunder
Moderna stock crashed Thursday after a third-party leaked the cancer vaccine data ahead of a hotly anticipated presentation.
13:00-15:00Oct 222 Stories
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
RAHWAY, N.J. & CAMBRIDGE, Mass., October 22, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in c
Moderna, Merck Shares Fall After Possible Melanoma Data Leak
Shares of Moderna Inc. and Merck & Co. fell after reports emerged about the results of the companies’ widely anticipated personalized melanoma vaccine, suggesting a possible leak of the data that’s slated to be released this weekend.
08:00-10:00Oct 222 Stories
Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Was There Any Sign Merck Stock Would Run?
For questions about this article or underlying research, email help@trefis.com.
12:00-17:00Oct 212 Stories
Merck (MRK) Laps the Stock Market: Here's Why
The latest trading day saw Merck (MRK) settling at $149.88, representing a +1.07% change from its previous close.
Why This Pharma Pro Likes Johnson & Johnson, Eli Lilly, and Merck Stock
Despite rising interest rates and the uncertainty of midterm elections, Asad Haider of Goldman Sachs sees promise in Big Pharma and biotech.
04:00Oct 216 Stories
Global Bioprocessing Support Services Market Report 2026 | Capitalize on $4.13B by 2030 as Thermo Fisher, Merck, Sartorius and Samsung Biologics Scale Single-Use Solutions
Boost ROI by outsourcing services, adopting single-use integrated platforms, and standardizing scale-up, optimization and compliance to cut costs and speed production.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Bioprocessing Support Services Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global bioprocessing support services market is experiencing rapid expansion, driven by increasing biopharmaceutical production, greater outsourcing of development and manufacturing
Global Cell Culture Media and Single-Use Reagents Market Report 2026 | Capitalize on 13.6% CAGR to $8.34B by 2030 with Thermo Fisher, Merck, Sartorius and Lonza
Boost ROI with integrated single-use bioreactors that reduce contamination, setup time, cleaning, footprint and operating costs while improving scalability.Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Cell Culture Media and Single-Use Reagents Market Report 2026" has been added to ResearchAndMarkets.com's offering. Cell Culture Media and Single-Use Reagents Market Poised to Reach $8.34 Billion by 2030 The global cell culture media and single-use reagents market is experiencing rapid expansion, sup
02:00Oct 211 Story
22:00Oct 201 Story
17:00-20:00Oct 192 Stories
Silence Therapeutics (SLN) Gets 130% Premium Offer From Merck, Shares Surge Over 100%
Silence Therapeutics (NASDAQ:SLN) kicked off the trading week by more than doubling its share price, as investors snapped up its shares following Merck KGaA’s offer to acquire the company for a 130-percent premium. In separate statements on the same day, Merck KGaA and Silence said that they have agreed to merge in an all-cash transaction […]
Better Dividend Stock: Merck vs. Bristol Myers Squibb
Key TakeawaysBristol Myers Squibb yields 4. 3% and Merck yields 2.
15:00-17:00Oct 192 Stories
Merck (MRK) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Merck (MRK) stood at $143.63, denoting a -1.59% move from the preceding trading day.
Silence Therapeutics to Be Acquired by Germany's Merck in $1.3 Billion Deal; Shares Surge
Silence Therapeutics' (SLN) US-listed shares soared Monday after the UK-based biotechnology company
12:00-15:00Oct 192 Stories
How Investors Are Reacting To Merck (MRK) Phase 3 Melanoma Results
Merck & Co., Inc. is preparing to present Phase 3 melanoma data for its personalized cancer treatment with Moderna, alongside progress in its KRAS inhibitor program, including MK-1084, which previously received Breakthrough Therapy Designation for first line advanced NSCLC with KRAS G12C mutations. The combination of late stage melanoma data with Keytruda and an advancing KRAS pipeline highlights how Merck is trying to broaden its oncology revenue base beyond any single product. We will now...
Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%
Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion.
11:00Oct 191 Story
12:00-14:00Oct 163 Stories
Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increases on a collision course with the drugs Wall Street is betting everything on.
Merck Stock: Watch This Price, Prepare To Profit From This Trade
Merck stock has been in an uptrend. A bullish options strategy aims to profit if the drugmaker's stock keeps rising.
Merck’s Rally Reflects Renewed Confidence, but Has the Market Priced in Too Much?
Merck & Co., Inc. (NYSE:MRK) has surged over 38% in 2026 so far, outperforming the broader market. Merck is no longer being valued like a pharmaceutical company whose biggest challenge is looming patent pressure. Yahoo Finance puts the stock at 15.29 times forward earnings, compared with 8.56 times at the end of September 2025. The […]
15:00Oct 152 Stories
How Has Merck's Story Changed?
Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand exactly what they hold, and the drugmaker's priorities have changed. During the fiscal Q4 2024 call in February 2025, executives noted that conditions for the GARDASIL vaccine in China remained challenging. By the August 4, 2026 call, management emphasized something else. So what does management talk up now.
What Could Merck (MRK) Reveal At ESMO 2026 About Its Oncology Pipeline?
Merck (NYSE:MRK) plans to unveil first-time pivotal Phase 3 oncology data at ESMO 2026, including melanoma and endometrial cancer trials. The company will share late-breaking results from multiple oncology pipeline programs that extend beyond its currently marketed cancer therapies. Merck is pairing the scientific presentations with an Oncology Investor Event focused on its next wave of cancer drug candidates and plans. The first-time pivotal Phase 3 oncology results at ESMO 2026 deserve to...
08:00-12:00Oct 152 Stories
Merck & Co., Inc. (MRK) Reports Promising Skin Cancer Trial Results for Keytruda and Personalized mRNA Vaccine
Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “International Concentrated Growth Strategy”. A copy of the letter can be downloaded here. The strategy outperformed its benchmark in the third quarter of 2026, as strong company-specific developments in biotechnology and digital platforms helped offset weakness in parts of […]
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
14:00Oct 31 Story
19:00Oct 21 Story
08:00-13:00Oct 13 Stories
Merck's Tulisokibart Data From Hidradenitis Suppurativa Trial Looks Solid, UBS Securities Says
Merck's (MRK) data from a phase 2b study evaluating tulisokibart in hidradenitis suppurativa looks s
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.
Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz
Moderna stock rallied by triple digits when positive news rolled in for its cancer vaccine. But is mRNA ready to return to the limelight?
06:00Oct 11 Story
14:00-17:00Sep 302 Stories
Why Merck (MRK) Dipped More Than Broader Market Today
In the latest trading session, Merck (MRK) closed at $145.31, marking a -2.66% move from the previous day.
Merck Says Investigational Skin Therapy Shows Potential
Merck & Co Inc. (NYSE:MRK) on Wednesday presented initial results from its Phase 2b MK-7240-012 trial at the European Academy of Dermatology and Venereology (EADV) 2026 Congress. Phase 2b Trial Delivers Positive Results The study evaluated tulisokibart—an investigational monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A)—in patients with moderate to severe hidradenitis suppurativa. The trial met its primary endpoint of Hidradenitis Suppurativa Clinical Response 50 (HiSCR
09:00-11:00Sep 302 Stories
What Is Merck Stock's Biggest Opportunity?
Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat
Citigroup just slapped a Sell rating on one of 2026's most explosive biotech stocks, warning that soaring investor hopes around a cancer vaccine partnership with Merck have carried the valuation into dangerous territory.